Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patien...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2015-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/7695 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850254291537756160 |
|---|---|
| author | Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova |
| author_facet | Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova |
| author_sort | Lyudmila Alexandrovna Suplotova |
| collection | DOAJ |
| description | Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patients (mean age: 57.2 years, range: 54.4–61.5 years), who were inadequately controlled on maximum tolerated doses of oral antidiabetic drugs (OADs) and in whom baseline insulin therapy with ultra-long-acting insulin degludec was initiated. The duration of treatment was 6 months. The list of procedures met the ‘Standard of primary medical care in non-insulin-dependent diabetes mellitus’, as approved by the Ministry of Health of the Russian Federation (12.28.2012 №1581-n). Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.Results: In the outpatient setting, insulin degludec was well tolerated by all the patients. During the observational period, there were no events of symptomatic hypoglycaemia confirmed by self-measured plasma glucose (blood glucose level <3.9 mmol/l). At the end of the observational period, HbA1c, fasting plasma glucose level (FPG) and postprandial (2 h after a meal) plasma glucose level (PPG) had decreased. Despite the fact that most of the patients had poor baseline glycaemic control, after 6 months of degludec therapy, 45% of the participants achieved a target HbA1c of <7.0%, and 45% achieved a target HbA1c of <8.0%. Improved glycaemic control was associated with increased quality of life scores on both physical and mental health components.Conclusion: In this primary health care clinical observational study, the initiation of insulin degludec in type 2 diabetes patients with poor glycaemic control on OADs was associated with the achievement of effective glycaemic control. In addition, it had a good safety profile, and it improved quality of life scores and adherence to the treatment. |
| format | Article |
| id | doaj-art-bb9f11fa3266492f955d458c1ee4ebc2 |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2015-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-bb9f11fa3266492f955d458c1ee4ebc22025-08-20T01:57:09ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782015-12-01184929810.14341/DM76957277Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practiceLyudmila Alexandrovna Suplotova0Nikolay Valer'evich Plotnikov1Natal'ya Valer'yanovna Romanova2Larisa Nikolaevna Bel’chikova3Ekaterina Viktorovna Khieva4Marina Vladimirovna Shestakova5Tyumen State Medical UniversityRegional clinical hospital, KurganRegional clinical hospital №2, TyumenRegional clinical hospital №1, TyumenRegional clinical hospital №2, TyumenEndocrinology Research Centre; Sechenov First Moscow State Medical UniversityAim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patients (mean age: 57.2 years, range: 54.4–61.5 years), who were inadequately controlled on maximum tolerated doses of oral antidiabetic drugs (OADs) and in whom baseline insulin therapy with ultra-long-acting insulin degludec was initiated. The duration of treatment was 6 months. The list of procedures met the ‘Standard of primary medical care in non-insulin-dependent diabetes mellitus’, as approved by the Ministry of Health of the Russian Federation (12.28.2012 №1581-n). Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.Results: In the outpatient setting, insulin degludec was well tolerated by all the patients. During the observational period, there were no events of symptomatic hypoglycaemia confirmed by self-measured plasma glucose (blood glucose level <3.9 mmol/l). At the end of the observational period, HbA1c, fasting plasma glucose level (FPG) and postprandial (2 h after a meal) plasma glucose level (PPG) had decreased. Despite the fact that most of the patients had poor baseline glycaemic control, after 6 months of degludec therapy, 45% of the participants achieved a target HbA1c of <7.0%, and 45% achieved a target HbA1c of <8.0%. Improved glycaemic control was associated with increased quality of life scores on both physical and mental health components.Conclusion: In this primary health care clinical observational study, the initiation of insulin degludec in type 2 diabetes patients with poor glycaemic control on OADs was associated with the achievement of effective glycaemic control. In addition, it had a good safety profile, and it improved quality of life scores and adherence to the treatment.https://www.dia-endojournals.ru/jour/article/view/7695type 2 diabetes mellitusinsulin degludecglycaemic controlhypoglycaemiaquality of life |
| spellingShingle | Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice Сахарный диабет type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life |
| title | Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice |
| title_full | Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice |
| title_fullStr | Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice |
| title_full_unstemmed | Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice |
| title_short | Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice |
| title_sort | data on the first experience of insulin degludec tresiba r treatment for type 2 diabetes in daily clinical practice |
| topic | type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life |
| url | https://www.dia-endojournals.ru/jour/article/view/7695 |
| work_keys_str_mv | AT lyudmilaalexandrovnasuplotova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT nikolayvalerevichplotnikov dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT natalyavaleryanovnaromanova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT larisanikolaevnabelchikova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT ekaterinaviktorovnakhieva dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT marinavladimirovnashestakova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice |